SINGAPORE — BOSTON — In results described by cardiologists as a historic leap forward for preventative medicine, international researchers published findings demonstrating the complete reversal of established arterial plaque in non-human primate models. Rather than cutting DNA strands, the therapy utilizes transient epigenetic editing to quiet lipid-storing inflammatory receptors in vascular endothelium.
Dissolving Plaque Through Epigenetic Reprogramming
Atherosclerosis has historically been considered an irreversible progressive disease managed primarily through cholesterol-lowering statins and invasive vascular stenting. In the eight-month trial, intravenous delivery of targeted lipid nanoparticles silenced PCSK9 and inflammatory endothelial markers, prompting macrophages to safely clear calcified blockages.
“We are moving from disease slowing to genuine biological reversal. The ability to dissolve arterial blockages non-invasively could reshape adult life expectancy globally.”
— Dr. Henrik Lindqvist, Principal Investigator, Karolinska Cardiovascular Institute
Safety Profile and Absence of Genomic Alterations
Detailed genomic sequencing confirmed zero off-target DNA breaks, as the molecular machinery relies on reversible methylation tags that degrade naturally within thirty-six hours of administration.
“Epigenetic editing provides the precision of genetics without the permanent risks of cutting human chromosomes.”— Dr. Sarah Chen, Professor of Genomic Medicine, Harvard Medical School
Path Toward Phase-I Human Clinical Trials
Regulatory authorities in Switzerland and the United States have scheduled joint scientific review panels to evaluate the protocol for human safety trials slated to begin late next year.